-
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold
under the
trade name Zevalin, is a
monoclonal antibody radioimmunotherapy treatment...
- 2002, the
United States Food and Drug
Administration (FDA)
approved ibritumomab tiuxetan (Zevalin),
which is an anti-CD20
monoclonal antibody conjugated...
- A
radioligand is a
microscopic particle which consists of a
therapeutic radioactive isotope and the cell-targeting
compound - the ligand. The
ligand is...
- Iodine-131-sodium
iodide hyperthyroidism and
thyroid cancer Yttrium-90-
ibritumomab tiuxetan (Zevalin) and Iodine-131-tositumomab (Bexxar)
refractory lymphoma...
-
antibody specific for CD20,
developed from its
parent antibody Ibritumomab. As with
ibritumomab,
rituximab targets CD20,
making it
effective in
treating certain...
-
Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox...
- in
drugs such as
Yttrium Y 90-DOTA-tyr3-octreotide and
Yttrium Y 90
ibritumomab tiuxetan for the
treatment of
various cancers,
including lymphoma, leukemia...
-
affinity of the
triaminopentacarboxylate scaffold for
metal ions. In
ibritumomab tiuxetan, the
chelator tiuxetan is a
modified version of DTPA
whose carbon...
- mitoxantrone, methotrexate, prednisone, rituximab,
vincristine and 90Y-
ibritumomab tiuxetan.[citation needed] One
combination for
stage III/IV relapsed...
-
neoplasm or is not
accessible in
normal cells. 131I
tositumomab and 90Y
ibritumomab tiuxetan were the
first agents of radioimmunotherapy, and they were approved...
